Posterior subtenon injection of triamcinolone acetonide reduces the use of intravitreal bevacizumab for diffuse diabetic macular edema
- Conditions
- Diffuse Diabetic Macular Edema
- Registration Number
- JPRN-UMIN000011656
- Lead Sponsor
- TT East Japan Tohoku Hospital
- Brief Summary
Subtenon triamcinolone acetonide (STTA)-treated eyes, as compared to their controls, had significantly more regression of foveal thickness (FT) and improvement of visual acuity (VA) at several time points during the study. The required number of intravitreal injection of bevcizumab (IVB) injections in STTA-treated eyes during the study was 5.00 plus-minus 1.75, which was significantly less than 7.95 plus-minus 1.57 in the control eyes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Not provided
Eyes with severe proliferative retinopathy were excluded from the study. Patients with a history of focal or pan retinal photocoagulation and/or cataract surgery in either eye within the 6 months prior to entry into the study, and patients who had previous therapies for DDME, including grid laser treatment, intravitreal injection of any drugs, and/or vitreous surgery, were excluded from this study. Patients with systemic disorders other than hypertension and hypercholesterolemia were excluded from this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Foveal thickness were monitored monthly for 1-year. The total number of intravitreal injections of bevacizumab injections during the follow-up
- Secondary Outcome Measures
Name Time Method logMAR visual acuity and intraocular pressure